Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
6
×
life sciences
national blog main
san francisco blog main
6
×
biotech
fda
national top stories
new york blog main
san diego blog main
san francisco top stories
indiana blog main
new york top stories
raleigh-durham blog main
san diego top stories
seattle blog main
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana top stories
investing
national
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
boston university
cancer
diabetes
medical devices
novartis
regeneron pharmaceuticals
What
patients
6
×
drug
fda
bio
help
market
medicine
million
roundup
startup
advantages
ago
alnylam
analytics
approve
aren’t
awaits
bar
beta
biofourmis
biological
bionics
blood
brings
cancer
closed
crossed
data
decades
decision
developers
developing
device
devices
diabetes
digital
discovered
driven
drugs
eisai
Language
unset
Current search:
patients
×
" clinical trials "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision